Data set from Dozio E, Vianello E, Sitzia C, Ambrogi F, Benedini S, Gorini S, Rampoldi B, Rigolini R, Tacchini L, Romanelli MMC. Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health. J Clin Med. 2020 Feb 6;9(2):454. doi: 10.3390/jcm9020454. PMID: 32041319; PMCID: PMC7074501.

Data set from the article Dozio E, Vianello E, Sitzia C, Ambrogi F, Benedini S, Gorini S, Rampoldi B, Rigolini R, Tacchini L, Romanelli MMC. Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health. J Clin Med. 2020 Feb 6;9(2):454. doi: 10.3390/jcm9020454. PMID: 32041319; PMCID: PMC7074501. <strong>Abstract</strong> A decline in metabolic health may take place before observing any alteration in the levels of the traditional metabolic markers. New indicators of metabolic derangement are therefore compelling. Irisin is a myokine with important metabolic functions. The role of irisin as a metabolic biomarker in humans has not been fully established yet. We quantified plasma irisin and esRAGE in 106 apparently healthy individuals and we performed a cluster analysis to evaluate their associations with metabolic profile. Plasma levels of various traditional markers of metabolic risk (i.e., glucose and lipid levels) were all within the ranges of normality. We identified two clusters of individuals. Compared to cluster 2, individuals in cluster 1 had higher irisin levels, a metabolic profile shifted toward the limits of the reference ranges and lower esRAGE levels. The traditional metabolic blood tests seem not to be enough to identify a metabolic decline early. Irisin increase and esRAGE decrease may reflect a metabolic derangement at the beginning of its development. The role of these molecules as early biomarkers of decline of metabolic health seems an interesting topic to be further explored.